Acute effects of cinacalcet on arterial stiffness and ventricular function in hemodialysis patients: A randomized

Aurélie Poulin1, Pierre-Luc Bellemare, Catherine Fortier

  • 1CHU de Québec Research Center, L'Hôtel-Dieu de Québec Hospital Department of Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.

Medicine
|May 25, 2017
PubMed

Insights

Cinacalcet, a medication that lowers calcium and parathyroid hormone, did not significantly improve arterial stiffness or cardiac function in patients with end-stage kidney disease. This 7-day study found no significant changes in blood pressure or vascular stiffness parameters.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Serum calcium (Ca) influences vascular tone and myocardial contractility.
  • Previous research indicated hemodialysis-induced Ca reduction improves arterial stiffness.
  • Cinacalcet, a calcimimetic, lowers Ca and parathyroid hormone (PTH).

Purpose of the Study:

  • To investigate if acute Ca lowering with cinacalcet improves vascular stiffness.
  • To assess the impact of cinacalcet on myocardial diastolic dysfunction.

Main Methods:

  • Double-blinded, randomized, placebo-controlled crossover study.
  • 21 end-stage kidney disease patients on hemodialysis received placebo-cinacalcet or cinacalcet-placebo for 7 days.
  • Arterial stiffness (cf-PWV, cr-PWV, carotid distension) and cardiac function (echocardiography) were assessed.

Main Results:

  • Cinacalcet significantly reduced PTH and ionized Ca levels.
  • No significant reduction in carotid-femoral pulse wave velocity (cf-PWV) was observed.
  • No significant changes in central blood pressure, brachial/carotid stiffness, or echocardiographic parameters were found.

Conclusions:

  • One week of daily cinacalcet (30 mg) did not significantly impact arterial stiffness.
  • The treatment showed no significant effect on peripheral/central blood pressures or cardiac function.
  • Further research may be needed to explore longer-term effects or different dosages.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
613
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.0K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
1.8K